The major focus of therapy for cardiogenic shock extends beyond the cardiovascular system,
aiming to enhance cardiac and end-organ perfusion. Identification of impending shock and …

Cardiogenic shock (CS) is a life-threatening medical condition that requires prompt
recognition and treatment. The use of standardized CS criteria, such as the Society for …

Opinion statement The use of percutaneous, non-durable mechanical circulatory support
(MCS) for cardiogenic shock (CS) is growing; however, large, randomized clinical trials …

Treating a patient with cardiogenic shock has been historically one of the most challenging
tasks in the everyday clinical practice for physicians in the emergency departments, ICUs …

The use of tMCS, as a bridge to recovery or heart replacement therapy in patients with
refractory cardiogenic shock has grown significantly over the past decade. Multiple device …

Cardiogenic shock is characterized by tissue hypoxia caused by circulatory failure arising
from inadequate cardiac output. In addition to treating the pathologic process causing …

Purpose of review To provide a contemporary concise overview of the currently available
mechanical circulatory support (MCS) devices and the emerging concepts in the …

Randomized controlled trials have been difficult to conduct in this patient population; until
such trials are performed, implementing shock teams and protocols has been associated …

Despite advancements in algorithms concerning the management of cardiogenic shock,
current guidelines still lack the adequate integration of mechanical circulatory support …

Abstract Treatment strategies to combat cardiogenic shock (CS) have remained stagnant
over the past decade. Mortality rates among patients who suffer CS after acute myocardial …